NIT-OCCLUD PDA Phase II Sentinel Trial

PFM Medical, Inc357 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of the Nit-Occlud -PDA Occlusion System for transcatheter closure of PDA with minimum angiographic diameter less than 4 mm, and to compare one year safety and efficacy outcomes with recommended OPCs.

The purpose of this clinical investigation is to evaluate whether transcatheter occlusion of PDAs with a minimum vessel diameter of 4 mm or smaller, by means of permanent implantation of the Nit-Occlud Spiral Coil for PDA Occlusion, is safe and effective. The device used for this purpose is a set of two items named "Nit-Occlud - PDA Occlusion System": * Nit-Occlud coils, 2 types: flexible (3 sizes) and medium (3 sizes) * Introducer Sheath, F4 or F5 85cm. The intended use of the device is the percutaneous, transluminal closure of PDA with an internal diameter or 4mm and smaller in patients who comply with the selection criteria. The investigation will continue until the sponsor receives FDA approval for commercial distribution and implantation of the system, or until the project is terminated by the sponsor or by the investigators. The objectives of this study are: 1. To determine the safety of the spiral coil by monitoring and reporting deaths and adverse events associated with the device and device placement. 2. To determine the effectiveness of the spiral coil by evaluating clinical and echocardiographic occlusion rates.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

357

Conditions

Ductus Arteriosus, Patent

Interventions

Transcatheter PDA CoilDEVICE

The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PDA with 4 mm or smaller minimum diameter by color Doppler * Patent weight \> 5 Kg, Age 6 months to 21 years (Patients older than 21 years may have device implant and be included in a study registry.) * Previous treatment by surgery or Nit-Occlud device with residual PDA noted at least 6 months after the procedure * Angiographic minimum PDA diameter (D1) less than 4 mm. (Patients with angiographic diameters larger than 4 mm and smaller or equal to 5 mm may have device implant and be included in a study registry.) Exclusion Criteria: * Associated cardiac anomalies requiring surgery * Known bleeding or blood clotting disorders * Ongoing febrile illness * Pregnancy * Pulmonary hypertension/increased pulmonary vascular resistance (\>5 Wood Units) * Known hypersensitivity to contrast medium

Locations (15)

Mattel Children's Hospital at UCLA

Los Angeles, California, United States

Children's Hospital Central California

Madera, California, United States

Outcomes

Primary Outcomes

Objective Performance Criteria (OPC) Technical Success at Implant

Time frame: One year

Clinical Closure and Echocardiographic Closure at 12 month follow-up

Time frame: One year

Serious Adverse Events and Mortality at 12 months

Time frame: One year

Total Device or Procedure Related Adverse Events

Time frame: One year

Secondary Outcomes

Composite Success. That is technical success, clinical and echocardiographic closure, and absence of device or procedure related death or serious AE at 12 months follow-up

Time frame: One year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.